<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01490658</url>
  </required_header>
  <id_info>
    <org_study_id>NN4440-1753</org_study_id>
    <nct_id>NCT01490658</nct_id>
  </id_info>
  <brief_title>Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Fed Healthy Volunteers</brief_title>
  <official_title>A Randomized, Single-Blind, Three-Period Crossover Study Examining the Single Dose Pharmacokinetics of Concomitantly Administered Repaglinide and Metformin Versus Combination Tablet Dosing (NN4440) in Fed Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in the United States of America (USA). The aim of this trial is to
      compare repaglinide and metformin as co-administered tablets and as a combination tablet.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">August 2006</completion_date>
  <primary_completion_date type="Actual">August 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Repaglinide and metformin AUC (Area under the Curve) fed state concomitant tablet administration</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Repaglinide and metformin AUC (Area under the Curve) NN4440 (2/500) combination tablet</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Repaglinide and metformin Cmax (maximum plasma concentration) fed state concomitant tablet administration</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>NN4440 (2/500) Cmax (maximum plasma concentration) combination tablet</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Repaglinide AUC after NN4440 (1/500) during fed state</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Repaglinide Cmax after NN4440 ((1/500) during fed state</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in physical examinations from screening</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">93</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Treatment period 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment period 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment period 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>repaglinide</intervention_name>
    <description>Single dose of 2 mg tablets administered immediately prior to a standard high fat breakfast concomitantly with metformin as separate tablets. Subjects will be randomised to receive trial drug on 3 separate dosing visits in varying order out of 6 possible treatment periods</description>
    <arm_group_label>Treatment period 1</arm_group_label>
    <arm_group_label>Treatment period 2</arm_group_label>
    <arm_group_label>Treatment period 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin</intervention_name>
    <description>Single dose of 500 mg tablets administered immediately prior to a standard high fat breakfast concomitantly with repaglinide as separate tablets. Subjects will be randomised to receive trial drug on 3 separate dosing visits in varying order out of 6 possible treatment periods</description>
    <arm_group_label>Treatment period 1</arm_group_label>
    <arm_group_label>Treatment period 2</arm_group_label>
    <arm_group_label>Treatment period 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>repaglinide and metformin combination tablet</intervention_name>
    <description>Single dose of 2 mg repaglinide/500 mg metformin (NN4440 2/500) or 1 mg repaglinide/500 mg metformin (NN4440 1/500)administered immediately prior to a standard high fat breakfast. Subjects will be randomised to receive trial drug on 3 separate dosing visits in varying order out of 6 possible treatment periods</description>
    <arm_group_label>Treatment period 1</arm_group_label>
    <arm_group_label>Treatment period 2</arm_group_label>
    <arm_group_label>Treatment period 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female volunteers (female not pregnant, lactating or breastfeeding)

          -  BMI (Body Mass Index) between 19-29 kg/m^2, both inclusive

          -  Fasting plasma glucose from 70-115 mg/dl

          -  Subject is judged to be in good health on the basis of their medical history, physical
             examination, ECG (electrocardiogram), and routine laboratory data

        Exclusion Criteria:

          -  Any clinically significant disease history, in the opinion of the Investigator, of
             systemic or organ disease

          -  Clinically significant abnormalities on pre-study clinical examination or any
             laboratory measurements during screening

          -  Positive results on screening for Hepatitis B surface antigen, Hepatitis C antibody
             and HIV (human immunodeficiency virus) antibody

          -  Positive results on the drug abuse/alcohol screen

          -  Any regular use of prescription or nonprescription drugs, including mega-vitamin or
             herbal supplement regimens, other than contraceptives, that cannot be stopped at least
             1 week prior to Visit 2 (trial product dose administration) and for the duration of
             the study

          -  Subject is currently a smoker (more than one cigarette per day or equivalent)

          -  Use of grapefruit or grapefruit juice within 7 days of trial product dose
             administration

          -  Blood donation, surgery or trauma with significant blood loss (500 mL) within the last
             2 months prior to dosing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <results_reference>
    <citation>Hoelscher D, Chu PL, Lyness W. Fixed-dose combination tablet of repaglinide and metformin is bioequivalent to concomitantly administered individual tablets of repaglinide and metformin : randomized, single-blind, three-period crossover study in healthy subjects. Clin Drug Investig. 2008;28(9):573-82.</citation>
    <PMID>18666804</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2011</study_first_submitted>
  <study_first_submitted_qc>December 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2011</study_first_posted>
  <last_update_submitted>February 9, 2017</last_update_submitted>
  <last_update_submitted_qc>February 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Repaglinide</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

